Investing in Healthcare Workers: What the Numbers Really Say About Returns on Wellbeing, Vaccines and Training

When hospital administrators weigh whether to fund a vaccination drive, a stress-management program or a new training scheme for their staff, one question tends to dominate the boardroom: will the money come back? A systematic review published in Public Health Reviews by researchers at the University of Catania and the National Public Health Organization in Athens set out to answer that question rigorously, examining nearly two decades of economic evidence on workplace interventions aimed at healthcare personnel. The verdict is nuanced: many interventions do pay off, but the eye-popping return-on-investment figures that circulate in policy debates deserve far more skepticism than they usually receive.

The research team, led by Pierluigi Catalfo and Caterina Ledda, searched PubMed, Scopus and Web of Science for peer-reviewed studies published between 2006 and 2024 that reported monetized economic outcomes for interventions targeting doctors, nurses and allied health workers. After screening 644 records and removing duplicates, twenty-eight studies made the final cut. Each was assessed for reporting quality using the CHEERS 2022 checklist and for risk of bias using the ECOBIAS tool, which together probe whether economic evaluations state their assumptions transparently and whether model-based estimates are built on defensible foundations. The majority of studies scored well on both counts, with more than 80 percent rated high quality under CHEERS criteria.

The interventions fell into four broad mechanistic categories, and this classification proved crucial for interpretation. Preventive and safety measures, such as vaccination campaigns and personal protective equipment, generate value primarily by averting infections, containing outbreaks and reducing sick leave. Occupational health and wellbeing programs, including stress-prevention strategies and disability management, work through reduced absenteeism and presenteeism. Professional development and human-capital investments, from residency training to advanced degrees, produce longer-term returns through workforce retention and productivity. Finally, research grants and documentation-improvement initiatives generate value through external funding capture and revenue recovery. Grouping studies this way allowed the reviewers to compare like with like rather than collapsing all economic evidence into a single, misleading ROI number.

Some of the strongest and most consistent findings came from vaccination. A Dutch modeling study of pertussis vaccination for healthcare workers estimated that every euro invested saved four euros in avoided outbreak costs, with a single neonatology outbreak costing nearly 49,000 euros. In Italy, a COVID-19 vaccination campaign at a major Roman hospital produced a benefit-to-cost ratio of 4.66, with total benefits of roughly 10.3 million euros against costs of about 2.2 million. A cost-effectiveness analysis in Lao PDR found that seasonal influenza vaccination for healthcare workers returned 2.88 Kip for every Kip spent, while also preventing thousands of lost workdays annually. These results align with a broader literature suggesting that public health interventions deliver median returns of around 14 to 1, with nationwide programs performing even better.

Workplace mental health and disability-management programs also showed encouraging economics. A preventive program in a Dutch academic hospital that combined screening, feedback and referral to occupational physicians generated net savings of between 244 and 651 euros per nurse, translating to a return of five to eleven euros for every euro invested. In an Italian pediatric hospital, a Workplace Disability Management Program yielded an ROI of 27.66 euros per euro invested, driven by substantial reductions in absenteeism and work limitations. A separate Italian pilot of psychological support for healthcare workers reported an ROI of 2.73 alongside a 60 percent reduction in sickness absence days. A stop-smoking program at another Italian hospital achieved an ROI of 1.90, with absenteeism falling by 85 percent within a year among participants.

Yet the review also surfaced findings that complicate the rosy narrative. A randomized controlled trial of a worksite vitality intervention among older Dutch hospital workers, which combined yoga, aerobic exercise, coaching and fruit provision, found no significant differences in costs or effects compared with usual care, and the employer-perspective ROI indicated a loss of 2.21 euros per euro invested. A participatory return-to-work program for temporary agency workers was more effective than usual care but also more costly, with an ROI below 1. These are not isolated anomalies. The reviewers note that randomized trials consistently produce fewer positive ROI results than observational or model-based studies, a pattern that echoes earlier warnings in the literature that ROI can be overestimated when long-term health benefits are discounted or ignored.

The most extreme figures in the review demand particular caution. A model-based analysis of personal protective equipment in low- and middle-income countries during the COVID-19 pandemic estimated an investment of 9.6 billion dollars would save nearly 2.3 million healthcare worker lives, producing a societal return of 755.3 billion dollars, equivalent to a 7,932 percent return. A similar Kenyan analysis reported an elevenfold return on PPE investment. These numbers are striking, but they rest on scenario assumptions about infection rates, mortality and the macroeconomic value of prevented deaths that cannot be directly translated into a hospital budget line. The reviewers explicitly caution that such estimates illustrate the potential scale of prevention benefits at a population level but should not be read as transferable institutional returns.

Geography and income setting matter enormously. The United States accounted for nearly 40 percent of the included studies, followed by the Netherlands and Italy, reflecting a heavy concentration of evidence from high-income countries. Studies from wealthier nations tended to adopt employer or institutional perspectives, measuring fiscal savings, productivity gains or revenue recovery. By contrast, analyses from low- and middle-income settings more often used model-based estimates of avoided mortality or macroeconomic productivity losses. A South African study of tertiary education funding for rural healthcare professionals calculated an internal rate of return of 63 percent, while a human-capital analysis across nine sub-Saharan African countries estimated that doctor emigration cost the region 2.17 billion dollars in lost training investment. These figures speak to different questions than a Dutch absenteeism study does, and the review argues they should never be compared side by side without adjustment.

Underlying all of this is a methodological problem that the authors frame as the central lesson of the review: ROI is not a single, standardized metric. Cost-benefit analysis, net present value, internal rate of return, cost-effectiveness ratios and social return on investment all monetize value differently, adopt different stakeholder perspectives and span different time horizons. An internal rate of return on medical education captures discounted financial returns over decades, while an employer-perspective ROI on absenteeism captures short-term fiscal savings. An incremental cost-effectiveness ratio tells policymakers whether additional costs buy additional health outcomes but says nothing about whether an employer recoups its spending. The heterogeneity in how benefits were monetized across the twenty-eight studies was so great that pooled quantitative synthesis was impossible, forcing the reviewers to rely on narrative interpretation organized by intervention mechanism.

The bottom line is a call for both investment and humility. The evidence supports workplace interventions for healthcare personnel as a legitimate component of health workforce strategy, particularly preventive measures, mental health support and structured professional development. But the authors are emphatic that return on investment should not serve as a stand-alone decision criterion. Critical health economics literature warns that ROI calculations can undervalue intangible benefits such as dignity, psychological wellbeing, safety culture and long-term workforce resilience while overemphasizing short-term monetizable gains. Future evaluations, the reviewers argue, should report their analytical perspective, time horizon, costing method and monetization assumptions transparently, include sensitivity analyses, and distinguish clearly between ROI and adjacent economic approaches. Only then can the numbers guiding decisions about the people who care for the rest of us be trusted to tell the whole story.

Subject of Research: Economic evaluation and return on investment of workplace interventions targeting healthcare personnel

Article Title: Effectiveness and economic impact of interventions targeting healthcare personnel: a systematic review of return on investment

Article References: Catalfo, P., Cantarella, C., Virgillito, D., Maltezou, H. C., & Ledda, C. (2026). Effectiveness and economic impact of interventions targeting healthcare personnel: a systematic review of return on investment. Public Health Reviews, 47, Article 1609191. https://doi.org/10.3389/phrs.2026.1609191

Image Credits: AI Generated

DOI: 10.3389/phrs.2026.1609191

Keywords: return on investment, healthcare personnel, systematic review, workplace interventions, occupational health, vaccination, burnout, professional development, cost-effectiveness, health workforce, absenteeism, public health economics